GlassScriptPhysician profile
James Mcavoy
NPI 1215917901
$4,694.72
in general payments reported to CMS, 2019-2025
35 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $263 · 2021: $1,406 · 2022: $734 · 2023: $796 · 2024: $771 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.93 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $773.29 | 2020-2025 | |
| Boston Scientific Corporation | $751.78 | 2021 | |
| Novo Nordisk INC | $613.47 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Shield Therapeutics INC | $408.05 | 2023-2024 | Accrufer |
| Novartis Pharmaceuticals Corporation | $273.88 | 2019-2025 | |
| Pfizer INC. | $249.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $188.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $179.98 | 2020-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.91 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $156.70 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $123.14 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $102.41 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $87.05 | 2020-2025 | Farxiga, Airsupra |
| Nestle Healthcare Nutrition INC. | $65.75 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $55.20 | 2020-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.25 | 2021-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $45.16 | 2021-2022 | |
| Corcept Therapeutics | $45.09 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $42.19 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.20 | 2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $29.18 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $23.20 | 2021 | |
| Eyevance Pharmaceuticals LLC | $23.20 | 2021 | |
| Lundbeck LLC | $23.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.71 | 2024 | Rexulti |
| Abbott Laboratories | $22.40 | 2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $21.46 | 2020 | |
| Exact Sciences Corporation | $21.41 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $18.71 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.55 | 2022 | |
| Mylan Specialty L.P. | $14.29 | 2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.20 | 2022 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcavoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.